Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Amgen logo
AmgenAMGN
$95.64B+8.8%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$400.37M-21.7%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 20252,9312,931
Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5049
Additional paid-in capital705,196657,561
Accumulated other comprehensive income (loss)(480)546
Accumulated deficit(220,977)(189,157)
Total stockholders’ equity486,720471,930
Total liabilities and stockholders’ equity$504,480$488,617

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s total liabilities & equity?
Oruka Therapeutics, Inc. (ORKA) reported total liabilities & equity of $504.48M in Q1 2026.
How has Oruka Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Oruka Therapeutics, Inc.'s total liabilities & equity increased by 33.8% year-over-year, from $377.11M to $504.48M.
What is the long-term trend for Oruka Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s total liabilities & equity has grown at a 57.5% compound annual growth rate (CAGR), from $50.43M to $488.62M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Oruka Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude